OA10411A - Nouveaux médicaments hormonaux et leur utilisation pour la correction des carences estrogéniques - Google Patents

Nouveaux médicaments hormonaux et leur utilisation pour la correction des carences estrogéniques Download PDF

Info

Publication number: OA10411A
Authority: OA; OAPI
Prior art keywords: estradiol; ester; estrogen; dose; conjugate
Prior art date: 1995-08-01

Application number

OA60985A

Other languages

English (en)

French (fr)

Inventor

Michel Lanquetin

Jacques Paris

Jean-Louis Thomas

Original Assignee

Theramex

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-08-01

Filing date

1997-04-01

Publication date

2001-12-06

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9481610&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=OA10411(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1997-04-01 Application filed by Theramex filed Critical Theramex

2001-12-06 Publication of OA10411A publication Critical patent/OA10411A/fr

Links

230000001076 estrogenic effect Effects 0.000 title claims description 6
230000007812 deficiency Effects 0.000 title claims description 3
238000012937 correction Methods 0.000 title description 3
229940088597 hormone Drugs 0.000 title description 3
239000000262 estrogen Substances 0.000 claims abstract description 16
239000000583 progesterone congener Substances 0.000 claims abstract description 14
230000003054 hormonal effect Effects 0.000 claims abstract description 9
VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 claims description 53
229960005309 estradiol Drugs 0.000 claims description 42
239000000902 placebo Substances 0.000 claims description 30
229940068196 placebo Drugs 0.000 claims description 30
150000002148 esters Chemical class 0.000 claims description 25
229960004190 nomegestrol acetate Drugs 0.000 claims description 22
IIVBFTNIGYRNQY-YQLZSBIMSA-N nomegestrol acetate Chemical compound C1=C(C)C2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 IIVBFTNIGYRNQY-YQLZSBIMSA-N 0.000 claims description 20
239000000203 mixture Substances 0.000 claims description 18
229940011871 estrogen Drugs 0.000 claims description 14
238000011282 treatment Methods 0.000 claims description 13
RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical class C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 claims description 11
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 6
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 6
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 6
239000008101 lactose Substances 0.000 claims description 6
229920000168 Microcrystalline cellulose Polymers 0.000 claims description 5
235000019813 microcrystalline cellulose Nutrition 0.000 claims description 5
239000008108 microcrystalline cellulose Substances 0.000 claims description 5
229940016286 microcrystalline cellulose Drugs 0.000 claims description 5
229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 5
235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 5
239000001267 polyvinylpyrrolidone Substances 0.000 claims description 5
239000008119 colloidal silica Substances 0.000 claims description 4
239000003086 colorant Substances 0.000 claims description 4
238000000034 method Methods 0.000 claims description 4
238000002360 preparation method Methods 0.000 claims description 4
239000000546 pharmaceutical excipient Substances 0.000 claims description 3
ZVVGLAMWAQMPDR-WVEWYJOQSA-N (8r,9s,13s,14s,17s)-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol;hydrate Chemical compound O.OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1.OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 ZVVGLAMWAQMPDR-WVEWYJOQSA-N 0.000 claims description 2
238000001035 drying Methods 0.000 claims description 2
229960003851 estradiol hemihydrate Drugs 0.000 claims description 2
238000005469 granulation Methods 0.000 claims description 2
230000003179 granulation Effects 0.000 claims description 2
239000008213 purified water Substances 0.000 claims description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 2
UEGPKNKPLBYCNK-UHFFFAOYSA-L magnesium acetate Chemical compound [Mg+2].CC([O-])=O.CC([O-])=O UEGPKNKPLBYCNK-UHFFFAOYSA-L 0.000 claims 2
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims 1
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims 1
229940124531 pharmaceutical excipient Drugs 0.000 claims 1
230000001225 therapeutic effect Effects 0.000 abstract description 4
229930182833 estradiol Natural products 0.000 description 15
DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 12
208000032843 Hemorrhage Diseases 0.000 description 8
206010060800 Hot flush Diseases 0.000 description 8
230000007423 decrease Effects 0.000 description 8
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 6
229940109239 creatinine Drugs 0.000 description 6
230000009245 menopause Effects 0.000 description 6
QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 5
206010006298 Breast pain Diseases 0.000 description 5
208000033830 Hot Flashes Diseases 0.000 description 5
208000006662 Mastodynia Diseases 0.000 description 5
210000004696 endometrium Anatomy 0.000 description 5
230000010072 bone remodeling Effects 0.000 description 4
210000000481 breast Anatomy 0.000 description 4
230000000694 effects Effects 0.000 description 4
FETSQPAGYOVAQU-UHFFFAOYSA-N glyceryl palmitostearate Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O FETSQPAGYOVAQU-UHFFFAOYSA-N 0.000 description 4
238000002559 palpation Methods 0.000 description 4
VOXZDWNPVJITMN-UHFFFAOYSA-N 13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol Chemical compound OC1=CC=C2C3CCC(C)(C(CC4)O)C4C3CCC2=C1 VOXZDWNPVJITMN-UHFFFAOYSA-N 0.000 description 3
208000002193 Pain Diseases 0.000 description 3
LCYXYLLJXMAEMT-SAXRGWBVSA-N Pyridinoline Chemical compound OC(=O)[C@@H](N)CCC1=C[N+](C[C@H](O)CC[C@H](N)C([O-])=O)=CC(O)=C1C[C@H](N)C(O)=O LCYXYLLJXMAEMT-SAXRGWBVSA-N 0.000 description 3
235000012000 cholesterol Nutrition 0.000 description 3
238000009472 formulation Methods 0.000 description 3
229960004911 nomegestrol Drugs 0.000 description 3
KZUIYQJTUIACIG-YBZCJVABSA-N nomegestrol Chemical compound C1=C(C)C2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(=O)C)(O)[C@@]1(C)CC2 KZUIYQJTUIACIG-YBZCJVABSA-N 0.000 description 3
239000000186 progesterone Substances 0.000 description 3
229960003387 progesterone Drugs 0.000 description 3
229910002016 Aerosil® 200 Inorganic materials 0.000 description 2
102000002260 Alkaline Phosphatase Human genes 0.000 description 2
108020004774 Alkaline Phosphatase Proteins 0.000 description 2
201000000736 Amenorrhea Diseases 0.000 description 2
206010001928 Amenorrhoea Diseases 0.000 description 2
102000004411 Antithrombin III Human genes 0.000 description 2
108090000935 Antithrombin III Proteins 0.000 description 2
102000005666 Apolipoprotein A-I Human genes 0.000 description 2
108010059886 Apolipoprotein A-I Proteins 0.000 description 2
108010039209 Blood Coagulation Factors Proteins 0.000 description 2
102000015081 Blood Coagulation Factors Human genes 0.000 description 2
108010049003 Fibrinogen Proteins 0.000 description 2
102000008946 Fibrinogen Human genes 0.000 description 2
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
108010028554 LDL Cholesterol Proteins 0.000 description 2
238000008214 LDL Cholesterol Methods 0.000 description 2
102000013566 Plasminogen Human genes 0.000 description 2
108010051456 Plasminogen Proteins 0.000 description 2
101800004937 Protein C Proteins 0.000 description 2
102000017975 Protein C Human genes 0.000 description 2
229940096437 Protein S Drugs 0.000 description 2
102000029301 Protein S Human genes 0.000 description 2
108010066124 Protein S Proteins 0.000 description 2
108010094028 Prothrombin Proteins 0.000 description 2
102100027378 Prothrombin Human genes 0.000 description 2
101800001700 Saposin-D Proteins 0.000 description 2
230000002411 adverse Effects 0.000 description 2
231100000540 amenorrhea Toxicity 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
229960005348 antithrombin iii Drugs 0.000 description 2
230000000740 bleeding effect Effects 0.000 description 2
239000003114 blood coagulation factor Substances 0.000 description 2
230000036772 blood pressure Effects 0.000 description 2
230000000052 comparative effect Effects 0.000 description 2
230000021615 conjugation Effects 0.000 description 2
230000035487 diastolic blood pressure Effects 0.000 description 2
230000002357 endometrial effect Effects 0.000 description 2
229940012952 fibrinogen Drugs 0.000 description 2
239000012634 fragment Substances 0.000 description 2
239000008103 glucose Substances 0.000 description 2
229940046813 glyceryl palmitostearate Drugs 0.000 description 2
150000002632 lipids Chemical class 0.000 description 2
208000010674 pelvic swelling Diseases 0.000 description 2
239000008194 pharmaceutical composition Substances 0.000 description 2
230000002062 proliferating effect Effects 0.000 description 2
229960000856 protein c Drugs 0.000 description 2
229940039716 prothrombin Drugs 0.000 description 2
230000003248 secreting effect Effects 0.000 description 2
230000035488 systolic blood pressure Effects 0.000 description 2
238000012360 testing method Methods 0.000 description 2
206010003439 Artificial menopause Diseases 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
ZAHDXEIQWWLQQL-IHRRRGAJSA-N Deoxypyridinoline Chemical compound OC(=O)[C@@H](N)CCCC[N+]1=CC(O)=C(C[C@H](N)C([O-])=O)C(CC[C@H](N)C(O)=O)=C1 ZAHDXEIQWWLQQL-IHRRRGAJSA-N 0.000 description 1
241000283073 Equus caballus Species 0.000 description 1
PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 1
108010044467 Isoenzymes Proteins 0.000 description 1
108010033266 Lipoprotein(a) Proteins 0.000 description 1
102000057248 Lipoprotein(a) Human genes 0.000 description 1
206010027514 Metrorrhagia Diseases 0.000 description 1
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
206010030247 Oestrogen deficiency Diseases 0.000 description 1
102000004067 Osteocalcin Human genes 0.000 description 1
108090000573 Osteocalcin Proteins 0.000 description 1
208000000450 Pelvic Pain Diseases 0.000 description 1
102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
229920003080 Povidone K 25 Polymers 0.000 description 1
RUJWZZRJSQGFCW-OGPYDZPMSA-N [(8s,9s,10r,13s,14s,17r)-17-acetyl-6,13-dimethyl-3-oxo-1,2,8,9,10,11,12,14,15,16-decahydrocyclopenta[a]phenanthren-17-yl] acetate;(8r,9s,13s,14s,17s)-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1.C1=C(C)C2=CC(=O)CC[C@@H]2[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 RUJWZZRJSQGFCW-OGPYDZPMSA-N 0.000 description 1
208000020560 abdominal swelling Diseases 0.000 description 1
YBCVMFKXIKNREZ-UHFFFAOYSA-N acoh acetic acid Chemical compound CC(O)=O.CC(O)=O YBCVMFKXIKNREZ-UHFFFAOYSA-N 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
230000004075 alteration Effects 0.000 description 1
238000013459 approach Methods 0.000 description 1
230000004872 arterial blood pressure Effects 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
239000000090 biomarker Substances 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
210000000988 bone and bone Anatomy 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
239000011575 calcium Substances 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
229960000913 crospovidone Drugs 0.000 description 1
230000004882 diastolic arterial blood pressure Effects 0.000 description 1
230000008034 disappearance Effects 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
208000035475 disorder Diseases 0.000 description 1
PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
-1 estradiol ester Chemical class 0.000 description 1
VOXZDWNPVJITMN-WKUFJEKOSA-N estradiol group Chemical group [C@@H]12CCC(O)[C@@]1(C)CC[C@@H]1C3=C(CC[C@@H]21)C=C(O)C=C3 VOXZDWNPVJITMN-WKUFJEKOSA-N 0.000 description 1
239000005556 hormone Substances 0.000 description 1
230000036571 hydration Effects 0.000 description 1
238000006703 hydration reaction Methods 0.000 description 1
229960002591 hydroxyproline Drugs 0.000 description 1
238000010191 image analysis Methods 0.000 description 1
238000005470 impregnation Methods 0.000 description 1
230000000938 luteal effect Effects 0.000 description 1
230000029849 luteinization Effects 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
208000007106 menorrhagia Diseases 0.000 description 1
210000004914 menses Anatomy 0.000 description 1
230000002503 metabolic effect Effects 0.000 description 1
230000000422 nocturnal effect Effects 0.000 description 1
230000027758 ovulation cycle Effects 0.000 description 1
230000036470 plasma concentration Effects 0.000 description 1
229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
208000001685 postmenopausal osteoporosis Diseases 0.000 description 1
230000002265 prevention Effects 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
238000010186 staining Methods 0.000 description 1
230000004873 systolic arterial blood pressure Effects 0.000 description 1
FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
230000002485 urinary effect Effects 0.000 description 1
210000002700 urine Anatomy 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens

Landscapes

Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Endocrinology (AREA)
Epidemiology (AREA)
Diabetes (AREA)
Reproductive Health (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Steroid Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

OA60985A 1995-08-01 1997-04-01 Nouveaux médicaments hormonaux et leur utilisation pour la correction des carences estrogéniques OA10411A (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
FR9509364A FR2737411B1 (fr)	1995-08-01	1995-08-01	Nouveaux medicaments hormonaux et leur utilisation pour la correction des carences estrogeniques

Publications (1)

Publication Number	Publication Date
OA10411A true OA10411A (fr)	2001-12-06

Family

ID=9481610

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
OA60985A OA10411A (fr)	1995-08-01	1997-04-01	Nouveaux médicaments hormonaux et leur utilisation pour la correction des carences estrogéniques

Country Status (30)

Country	Link
US (1)	US5891867A (cs)
EP (1)	EP0783310B1 (cs)
JP (1)	JPH10507207A (cs)
KR (1)	KR100450649B1 (cs)
CN (1)	CN1138547C (cs)
AP (1)	AP829A (cs)
AR (1)	AR004502A1 (cs)
AT (1)	ATE225659T1 (cs)
AU (1)	AU722355B2 (cs)
BR (1)	BR9606549A (cs)
CA (1)	CA2201368C (cs)
CZ (1)	CZ289706B6 (cs)
DE (1)	DE69624214T2 (cs)
DK (1)	DK0783310T3 (cs)
DZ (1)	DZ2078A1 (cs)
ES (1)	ES2184880T3 (cs)
FR (1)	FR2737411B1 (cs)
HU (1)	HU229843B1 (cs)
IL (1)	IL120558A (cs)
MA (1)	MA23946A1 (cs)
MX (1)	MX9702381A (cs)
MY (1)	MY117307A (cs)
NO (1)	NO312996B1 (cs)
OA (1)	OA10411A (cs)
PT (1)	PT783310E (cs)
RU (1)	RU2188641C2 (cs)
TN (1)	TNSN96101A1 (cs)
TW (1)	TW473390B (cs)
WO (1)	WO1997004784A1 (cs)
ZA (1)	ZA966545B (cs)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2754179B1 (fr) *	1996-10-08	1998-12-24	Theramex	Nouvelle composition hormononale et son utilisation
WO2001030355A1 (fr) *	1999-10-25	2001-05-03	Laboratoire Theramex	Medicament contraceptif a base d'un progestatif et d'un estrogene et son mode de preparation
US6787531B1 (en) *	1999-08-31	2004-09-07	Schering Ag	Pharmaceutical composition for use as a contraceptive
WO2001030356A1 (fr) *	1999-10-25	2001-05-03	Laboratoire Theramex	Composition hormonale a base d'un progestatif et d'un estrogene et son utilisation
US20020132801A1 (en) *	2001-01-11	2002-09-19	Schering Aktiengesellschaft	Drospirenone for hormone replacement therapy
FR2814074B1 (fr) *	2000-09-15	2003-03-07	Theramex	Nouvelles compositions estro-progestatives topiques a effet systemique
US20020151732A1 (en) *	2001-01-05	2002-10-17	Claes Ohlsson	Estrogen receptors
EP1390038A2 (en)	2001-05-16	2004-02-25	Endeavor Pharmaceuticals	Treatment of conditions relating to hormone deficiencies by administration of progestins
NZ591627A (en) *	2001-12-05	2012-09-28	Teva Womens Health Inc	Oral contraceptives to prevent pregnancy and diminish premenstrual symptomatology
US7008979B2 (en) *	2002-04-30	2006-03-07	Hydromer, Inc.	Coating composition for multiple hydrophilic applications
CA2771944A1 (en) *	2003-07-16	2005-01-27	Teva Women's Health, Inc.	Methods of hormonal treatment utilizing contraceptive regimens with continuous estrogen administration
US20070111975A1 (en) *	2004-10-07	2007-05-17	Duramed Pharmaceuticals, Inc.	Methods of Hormonal Treatment Utilizing Ascending-Dose Extended Cycle Regimens
US8022053B2 (en) *	2004-11-02	2011-09-20	Bayer Schering Pharma Aktiengesellschaft	Oral solid dosage forms containing a low dose of estradiol
AR065816A1 (es) *	2007-03-26	2009-07-01	Theramex	Regimen anticonceptivo oral

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4390531A (en) *	1981-08-10	1983-06-28	Syntex Pharmaceuticals International Ltd.	Method of contraception using peak progestogen dosage
US4826831A (en) *	1983-08-05	1989-05-02	Pre Jay Holdings Limited	Method of hormonal treatment for menopausal or post-menopausal disorders involving continuous administration of progestogens and estrogens
US4870066A (en) *	1986-08-11	1989-09-26	The University Of Kentucky Research Foundation	Method and composition for safely delaying parturition and synchronizing farrowing in swine
EP0483077B1 (en) *	1990-09-28	1995-12-06	I.F.L.O. S.a.s. di Giorgio e Aldo Laguzzi	A method for carrying out the synthesis of a contraceptive and menstrual cycle controlling drug having oncostatic, antikinetosic, preventive and therapeutic properties for treatment of mammary tumours and melanomas.
FR2695826B1 (fr) *	1992-09-21	1995-01-06	Theramex	Nouvelles compositions pharmaceutiques à base de dérivés de nomégestrol et leurs procédés d'obtention.

1995
- 1995-08-01 FR FR9509364A patent/FR2737411B1/fr not_active Expired - Fee Related
1996
- 1996-07-22 MA MA24321A patent/MA23946A1/fr unknown
- 1996-07-26 MY MYPI96003099A patent/MY117307A/en unknown
- 1996-07-29 JP JP9507406A patent/JPH10507207A/ja not_active Ceased
- 1996-07-29 DK DK96923018T patent/DK0783310T3/da active
- 1996-07-29 HU HU9900612A patent/HU229843B1/hu unknown
- 1996-07-29 AP APAP/P/1997/000979A patent/AP829A/en active
- 1996-07-29 DE DE69624214T patent/DE69624214T2/de not_active Expired - Lifetime
- 1996-07-29 MX MX9702381A patent/MX9702381A/es active IP Right Grant
- 1996-07-29 CZ CZ1997967A patent/CZ289706B6/cs not_active IP Right Cessation
- 1996-07-29 US US08/817,329 patent/US5891867A/en not_active Expired - Lifetime
- 1996-07-29 EP EP96923018A patent/EP0783310B1/fr not_active Expired - Lifetime
- 1996-07-29 CA CA2201368A patent/CA2201368C/fr not_active Expired - Lifetime
- 1996-07-29 AT AT96923018T patent/ATE225659T1/de active
- 1996-07-29 AU AU63674/96A patent/AU722355B2/en not_active Expired
- 1996-07-29 PT PT96923018T patent/PT783310E/pt unknown
- 1996-07-29 CN CNB96191100XA patent/CN1138547C/zh not_active Expired - Lifetime
- 1996-07-29 KR KR1019970702125A patent/KR100450649B1/ko not_active Expired - Lifetime
- 1996-07-29 IL IL12055896A patent/IL120558A/en not_active IP Right Cessation
- 1996-07-29 RU RU97108279/14A patent/RU2188641C2/ru active
- 1996-07-29 ES ES96923018T patent/ES2184880T3/es not_active Expired - Lifetime
- 1996-07-29 BR BR9606549A patent/BR9606549A/pt not_active Application Discontinuation
- 1996-07-29 WO PCT/IB1996/000754 patent/WO1997004784A1/fr not_active Ceased
- 1996-07-30 DZ DZ960122A patent/DZ2078A1/fr active
- 1996-07-31 AR ARP960103818A patent/AR004502A1/es not_active Application Discontinuation
- 1996-08-01 TN TNTNSN96101A patent/TNSN96101A1/fr unknown
- 1996-08-01 ZA ZA966545A patent/ZA966545B/xx unknown
- 1996-09-24 TW TW085111673A patent/TW473390B/zh not_active IP Right Cessation
1997
- 1997-03-26 NO NO19971449A patent/NO312996B1/no not_active IP Right Cessation
- 1997-04-01 OA OA60985A patent/OA10411A/fr unknown

Also Published As

Publication number	Publication date
PT783310E (pt)	2003-02-28
ATE225659T1 (de)	2002-10-15
NO312996B1 (no)	2002-07-29
CZ96797A3 (cs)	1998-08-12
ZA966545B (en)	1997-05-08
NO971449D0 (no)	1997-03-26
MY117307A (en)	2004-06-30
AU722355B2 (en)	2000-07-27
HUP9900612A3 (en)	1999-11-29
DE69624214D1 (de)	2002-11-14
TNSN96101A1 (fr)	2005-03-15
ES2184880T3 (es)	2003-04-16
IL120558A0 (en)	1997-07-13
IL120558A (en)	2002-09-12
CZ289706B6 (cs)	2002-03-13
EP0783310A1 (fr)	1997-07-16
AP829A (en)	2000-05-03
FR2737411B1 (fr)	1997-10-17
DE69624214T2 (de)	2003-07-10
HUP9900612A2 (hu)	1999-07-28
AR004502A1 (es)	1998-12-16
AU6367496A (en)	1997-02-26
KR970706004A (ko)	1997-11-03
HU229843B1 (en)	2014-09-29
DK0783310T3 (da)	2003-02-10
CA2201368C (fr)	2010-12-07
DZ2078A1 (fr)	2002-10-22
WO1997004784A1 (fr)	1997-02-13
MX9702381A (es)	1998-02-28
CN1167438A (zh)	1997-12-10
MA23946A1 (fr)	1997-04-01
NO971449L (no)	1997-05-30
JPH10507207A (ja)	1998-07-14
CA2201368A1 (fr)	1997-02-13
BR9606549A (pt)	1998-06-23
HK1005227A1 (en)	1998-12-31
RU2188641C2 (ru)	2002-09-10
TW473390B (en)	2002-01-21
FR2737411A1 (fr)	1997-02-07
AP9700979A0 (en)	1997-07-31
KR100450649B1 (ko)	2004-11-16
US5891867A (en)	1999-04-06
EP0783310B1 (fr)	2002-10-09
CN1138547C (zh)	2004-02-18

Publication	Publication Date	Title
EP0783310B1 (fr)	2002-10-09	Nouveaux medicaments hormonaux et leur utilisation pour la correction des carences estrogeniques
EP0613372B1 (fr)	2000-12-27	Implants sous-cutanes a base de derives de nomegestrol
FR2848112A1 (fr)	2004-06-11	Composition pharmaceutique pour administration transdermique ou transmuqueuse comprenant au moins un progestatif et/ou au moins un oestrogene, son procede de preparation et ses utilisations
HUE029434T2 (en)	2017-02-28	Procedure for emergency contraception
EP0956022B1 (fr)	2003-04-23	Composition hormonale constituee d'un compose estrogene et d'un compose progestatif
EP1227814B1 (fr)	2005-01-05	Composition hormonale a base de acetate de nomegestrol et d'un estrogene et son utilisation
EP2020236B1 (fr)	2016-01-27	Méthode contraceptive à base d'un progestatif et d'un estrogéne
EP0177654B1 (fr)	1989-05-31	Association synergique contraceptive
NZ262562A (en)	1996-04-26	Preparation of solvent free pharmaceutical compositions
CA2623024C (en)	2012-03-06	Use of estradiol valerate or estradiol combined with dienogest for the oral therapy of dysfunctional uterine bleeding in the form of oral contraceptives
EP1143978A2 (fr)	2001-10-17	Utilisation d'hormones sexuelles pour l'obtention d'une composition pharmaceutique nasale utile pour le traitement des saignements uterins indesirables
FR2823976A1 (fr)	2002-10-31	Nouvelle composition hormonale et son utilisation